2020 New Therapeutic Uses for Experimental Assets Projects

In 2020, NCATS issued funding for one cooperative agreement designed to match academic research groups with selected compounds from industry as part of the New Therapeutic Uses program. The goal is to use molecules that already have undergone significant research and development by the pharmaceutical industry to more quickly advance new treatments for patients.

Use of the Src Family Kinase Inhibitor Saracantinib in the Treatment of Pulmonary Fibrosis

National Jewish Health

Principal Investigators: Gregory Paul Downey, M.D. (National Jewish Health), Naftali Kaminski, M.D. (Yale University), Maria L. Padilla, M.D. (Mount Sinai School of Medicine)
Grant Number: 4-UH3TR002445-02

Scarring of the lung, termed pulmonary fibrosis (IPF), is a chronic, progressive, and usually fatal disorder. While two drugs have recently been approved for the treatment of pulmonary fibrosis, neither is curative and nearly 40% of patients stop taking the drug within a year because of side effects. We propose to study the use of saracatinib, a drug originally developed to treat certain types of cancers, in the treatment of pulmonary fibrosis in both preclinical models and in a Phase 1b/2a clinical trial.

Learn more about this project in the NIH RePORTER.